Cargando…
Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
Immune checkpoint inhibitor (ICI) immunotherapies have vastly improved therapeutic outcomes for patients with certain cancer types, but these responses only manifest in a small percentage of all cancer patients. The goal of the present study was to improve checkpoint therapy efficacy by utilizing an...
Autores principales: | Lou, Jiaying, Dong, Jialin, Xu, Ruijun, Zeng, Hui, Fang, Lijuan, Wu, Yi, Liu, Yang, Wang, Shibing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193643/ https://www.ncbi.nlm.nih.gov/pubmed/34060602 http://dx.doi.org/10.1042/BSR20204186 |
Ejemplares similares
-
Correction: Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
Publicado: (2022) -
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020) -
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer
por: Chen, Wanyuan, et al.
Publicado: (2019) -
Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus
por: Peng, Jiamin, et al.
Publicado: (2018) -
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)